<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251251</url>
  </required_header>
  <id_info>
    <org_study_id>FRN 63208</org_study_id>
    <secondary_id>FRN 63208</secondary_id>
    <nct_id>NCT00251251</nct_id>
  </id_info>
  <brief_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</brief_title>
  <acronym>RAFT</acronym>
  <official_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congestive heart failure (CHF) is a common health problem that leads to frequent
      hospitalizations and an increased death rate. In spite of advances in drug therapy, it
      remains a significant public health problem. Recently, a new therapy has been developed for
      advanced heart failure patients with a ventricular conduction abnormality. This new therapy,
      called cardiac resynchronization (CRT), is a device which stimulates the atrium, the right
      ventricle, and the left ventricle providing synchronization of the contraction of the heart
      chambers. It is the addition of this therapy to an implantable cardioverter defibrillator
      (ICD) that will be evaluated in this study. This study will compare whether the implantation
      of this new therapy device, in combination with an implantable cardioverter defibrillator,
      will reduce total mortality and hospitalizations for CHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular mortality is decreasing in most industrial countries, however mortality for
      congestive heart failure is increasing. The most important predictors of mortality in heart
      failure patients are depressed left ventricular function, severity of symptoms (NYHA class),
      and ventricular conduction abnormality manifested as wide QRS. Recent advances in
      pharmacological therapy including ACE inhibitors, beta-blocker and spironolactone have
      resulted in improvement of symptoms and reduction in mortality. Population epidemiological
      studies demonstrated that mortality and hospitalization rate for heart failure remains very
      high despite recent pharmacological therapeutic progress. Recent short-term clinical trials
      demonstrated that cardiac resynchronization therapy (CRT) is effective in improving symptoms
      of heart failure, functional capacity and quality of life in patients with moderate to severe
      heart failure and conduction abnormality optimally treated with drug therapy. However, the
      data for morbidity and mortality in mild to moderate heart failure is lacking.

      The objective of this trial is to determine if the addition of CRT to optimal pharmacological
      therapy and ICD is effect in reducing mortality and morbidity in patients with poor LV
      function, wide QRS and mild to moderate heart failure symptoms.

      This is a double-blinded randomized control trial. A total of 1800 patients with mild to
      moderate heart failure symptoms, LVEF ≤ 30%, and QRS ≥ 120 ms will be included in the study.
      Patients will be randomized to either &quot;ICD plus Optimal Medical Therapy (control)&quot; or
      &quot;CRT/ICD plus Optimal Medical Therapy (experimental)&quot; in a 1:1 randomization ratio. Patients
      in the control group will be implanted with a single or dual chamber ICD. Patients in the
      experimental group will receive a device with the capabilities of CRT and ICD. Optimal
      Medical Therapy will include ACE inhibitors and beta-blockers. Patients will be followed on a
      regular basis and will have clinical evaluation, quality of life assessment, and six minute
      walk tests performed. The primary outcome is a composite of total mortality and heart failure
      hospitalization. Secondary outcome measures will include total mortality, cardiovascular
      mortality, sudden arrhythmic death, health related quality of life and cost economics.
      Patient accruement is scheduled for 4.5 years and a minimum follow of 18 months.

      DFT sub study:

      Overview of sub-study Design Patients participating in the RAFT trial, at participating
      sites, will be randomized to have DFT testing or no testing at the time of device implant. Up
      to 450 patients will be eligible for enrollment at Canadian and European centres. The study
      will have two primary outcomes: a short-term safety outcome and a long-term efficacy outcome.
      The safety outcome will be a composite of all adverse events potentially related to DFT that
      occur within 30 days following ICD implant. The long-term efficacy outcome will be a
      composite of failed first appropriate clinical ICD shock and sudden death. This pilot study
      is intended primarily to confirm the anticipated rates of events and to demonstrate
      feasibility of enrollment, but will not have statistical power to determine if
      intra-operative DFT testing is associated with significant short-term risk. If complication
      rates are as high as predicted and enrollment is feasible, then a larger study would be
      justified to determine the impact of intra-operative DFT testing on long-term rates of failed
      appropriated ICD shocks and sudden death. Events rates determined in this pilot study would
      then be used to estimate the sample size of this larger study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome is a composite of all cause total mortality and hospitalization for CHF</measure>
    <time_frame>Study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden arrhythmic death</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive HF death</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalization rate</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHF hospitalization rate</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost economics</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1798</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>1. Optimal Medical therapy plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Optimal Medical Therapy plus CRT/ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical Therapy plus ICD</intervention_name>
    <description>ICD vs CRT/ICD</description>
    <arm_group_label>1. Optimal Medical therapy plus ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical Therapy plus CRT/ICD</intervention_name>
    <description>ICD vs CRT/ICD</description>
    <arm_group_label>2. Optimal Medical Therapy plus CRT/ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New York Heart Association (NYHA) Class II

          -  Left ventricular ejection fraction (LVEF) less than or equal to 30% by multigated
             acquisition scan (MUGA)/catheterization OR LVEF less than or equal to 30% and LV end
             diastolic dimension ≥ 60 mm (by echocardiogram) within 6 months prior to randomization

          -  Intrinsic QRS complex width ≥ 120 ms OR paced QRS measurement ≥ 200 ms

          -  ICD indication for primary or secondary prevention

          -  Optimal heart failure pharmacological therapy

          -  Normal sinus rhythm; OR chronic persistent atrial tachyarrhythmia with resting
             ventricular heart rate ≤ 60 beats per minute (bpm) and 6 minute hall walk ventricular
             heart rate of ≤ 90 bpm; OR chronic persistent atrial tachyarrhythmia with resting
             ventricular heart rate &gt; 60 bpm and 6 minute hall walk ventricular heart rate of &gt; 90
             bpm and booked for atrioventricular junction ablation.

        Exclusion Criteria:

          -  Intravenous inotropic agent in the last 4 days

          -  Patients with a life expectancy of less than one year from non-cardiac cause

          -  Expected to undergo cardiac transplantation within one year (status I)

          -  In hospital patients who have acute cardiac or non-cardiac illness that requires
             intensive care

          -  Uncorrected or uncorrectable primary valvular disease

          -  Restrictive, hypertrophic, or reversible form of cardiomyopathy

          -  Severe primary pulmonary disease such as cor pulmonale

          -  Tricuspid prosthetic valve

          -  Patients with an existing ICD (patients with an existing pacemaker may be included if
             the patients satisfy all other inclusion/exclusion criteria)

          -  Coronary revascularization (coronary artery bypass graft surgery [CABG] or
             percutaneous coronary intervention [PCI]) &lt; 1 month if previously determined LVEF &gt;
             30%. Patients with a more recent revascularization can be included if a previously
             determined LVEF was ≤ 30%.

          -  Patients with an acute coronary syndrome including myocardial infarction (MI) can be
             included if the patients have had a previous MI with LV dysfunction (LVEF ≤ 30%).

          -  Patients included in another clinical trial that will affect the objectives of this
             study

          -  History of noncompliance to medical therapy

          -  Unable or unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Wells, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary/Foothill Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NB Heart Centre Research Initiative</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Care</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4 W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2005</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Anthony Tang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Congestive heart failure</keyword>
  <keyword>Multicentre randomized controlled trial</keyword>
  <keyword>Defibrillator</keyword>
  <keyword>Cardiac resynchronization</keyword>
  <keyword>Sudden death/mortality</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>ICD indication</keyword>
  <keyword>NYHA Class II</keyword>
  <keyword>LVEF &lt;/equal to 30%</keyword>
  <keyword>QRS &gt;/equal to 120 ms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

